Antiretroviral Agents in HIV-1 (trial)

DHHS Adult HIV 2013

DHHS HIV GUIDELINES Apps brought to you free of charge courtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/309990

Contents of this Issue

Navigation

Page 29 of 31

Table 7. Advantages and Disadvantages of Antiretroviral Components Recommended as Initial Antiretroviral Therapy ARV Agent(s) Advantages Disadvantages Dual-NRTI pairs a (cont'd) TDF/FTC • Better virologic responses than with ZDV/3TC • Better virologic responses than with ABC/3TC in patients with baseline HIV RNA >100,000 copies/mL in ACTG 5202 study; however, this was not seen in the HEAT study • Active against HBV; recommended dual NRTI for HIV/HBV coinfection • Once-daily dosing • No food effect • Coformulated (TDF/FTC, EFV/TDF/FTC, and RPV/ TDF/FTC) • No cumulative TAM-mediated resistance • Potential for renal impairment, including Fanconi syndrome and acute renal insufficiency • Early virologic failure of NVP + TDF + (FTC or 3TC) in small clinical trials • Potential for decrease in BMD ZDV/3TC • Coformulated (ZDV/3TC and ZDV/3TC/ABC) • No food effect (although better tolerated with food) • Preferred dual NRTI in pregnant women • Bone marrow suppression, especially anemia and neutropenia • GI intolerance, headache • Mitochondrial toxicity, including lipoatrophy, lactic acidosis, hepatic steatosis • Compared with TDF/FTC, inferior in combination with EFV • Less CD4 increase compared with ABC/3TC • Twice-daily dosing a Agents listed in alphabetical order. Selecting a Treatment Regimen 28

Articles in this issue

Archives of this issue

view archives of Antiretroviral Agents in HIV-1 (trial) - DHHS Adult HIV 2013